McKesson (MCK) Stock: Healthcare Giant Ready to Rally?

McKesson Corporation (NYSE: MCK) is one of the largest healthcare services and pharmaceutical distribution companies in the United States. While its enormous revenue base can make the company look like a low-growth distributor, the investment story is actually more interesting: strong earnings growth, specialty pharmaceuticals, oncology, biopharma services and aggressive share repurchases are increasingly driving McKesson's value.

After reaching a 52-week high of about $999 in March 2026, MCK recently traded around $859, leaving the stock roughly 14% below that high. (MarketWatch) The question is whether this pullback represents an opportunity or simply a pause after a major rally.

Strong Fiscal 2026 Performance

McKesson finished fiscal 2026 with impressive numbers.

Full-year revenue increased 12% to $403.4 billion, while adjusted earnings per share increased 18% to $39.11. Operating cash flow reached $6.2 billion and free cash flow was approximately $5.4 billion. (McKesson)

That combination is important.

McKesson operates in a business where revenue is enormous but margins are relatively thin. Therefore, investors should focus less on headline revenue and more on adjusted EPS, free cash flow and operating-profit growth.

On those measures, the company has been performing strongly.

Fiscal 2027 Guidance Looks Encouraging

Management's initial fiscal 2027 outlook called for adjusted EPS of $43.80–$44.60, representing approximately 12%–14% growth over fiscal 2026. (McKesson)

And the outlook has since become more encouraging.

After its first-quarter fiscal 2027 results in August, McKesson raised its full-year adjusted EPS guidance, reinforcing investor confidence in the company's earnings trajectory. (Business Wire)

For a company of McKesson's scale, maintaining double-digit EPS growth is a significant achievement.

Oncology Is a Major Growth Engine

One of the most important parts of McKesson's future is its exposure to oncology and specialty pharmaceuticals.

Cancer treatments are becoming increasingly complex and expensive, creating opportunities for specialized distributors and service providers.

McKesson's Oncology & Multispecialty segment has a long-term adjusted operating-profit growth target of 13%–16%, significantly higher than the company's traditional North American pharmaceutical distribution business. (McKesson)

This is one of the reasons McKesson isn't simply a low-margin drug wholesaler.

Its specialty-healthcare capabilities could become increasingly important as pharmaceutical innovation shifts toward complex therapies.

Biopharma Services Add Another Growth Layer

McKesson is also expanding its role in the pharmaceutical ecosystem.

Its biopharma services business supports manufacturers with areas such as patient access, distribution, commercialization and other services.

This creates a potentially attractive business model because McKesson can participate in the growth of innovative medicines without having to discover and develop those drugs itself.

Management has specifically identified Oncology and Biopharma Services as high-growth, high-margin areas for future investment. (McKesson)

Prescription Technology Is Another Opportunity

McKesson's Prescription Technology Solutions business is another area worth watching.

Management's long-term target calls for 10%–13% adjusted segment operating-profit growth. (McKesson)

Technology can potentially improve pharmacy efficiency, prescription management and patient access while providing McKesson with higher-margin revenue streams than traditional drug distribution.

This diversification could gradually improve the company's overall earnings profile.

Share Buybacks Are a Major Catalyst

One of the most attractive aspects of MCK is capital allocation.

McKesson entered fiscal 2027 with a $7.7 billion total share-repurchase authorization, including a new $5 billion increase approved by the board and a $2.25 billion accelerated share-repurchase program. (McKesson)

Why does this matter?

If McKesson continues generating billions in free cash flow and uses a significant portion to retire shares, earnings are spread across fewer outstanding shares.

That can accelerate EPS growth even when overall business growth is more moderate.

For long-term shareholders, buybacks can therefore become an important part of the total-return story.

Dividend Growth Adds Income

McKesson isn't traditionally viewed as a high-yield healthcare stock, but its dividend policy has been improving.

In August 2026, the company announced a 15% increase in its quarterly dividend to $0.94 per share, marking its tenth consecutive year of dividend growth. (Business Wire)

The yield isn't the main reason to own MCK, but consistent dividend growth combined with aggressive buybacks provides another source of shareholder returns.

The Business Has Defensive Characteristics

Healthcare demand is generally more resilient than many other areas of the economy.

People continue requiring prescription medicines and medical treatments during recessions, which gives McKesson a relatively defensive underlying business.

The company's enormous distribution network also creates significant scale advantages.

Pharmacies, healthcare providers and pharmaceutical manufacturers depend on reliable distribution, making McKesson an important link in the healthcare supply chain.

But MCK Isn't Risk-Free

Despite its attractive fundamentals, investors shouldn't treat McKesson as a risk-free healthcare stock.

Thin Margins

Drug distribution is a high-volume, relatively low-margin business. Small changes in operating costs or pricing can therefore have a meaningful effect on profitability.

Pharmaceutical Pricing Pressure

Government policies, drug pricing reforms and negotiations can affect the economics of pharmaceutical distribution.

Customer Concentration

Large pharmacy chains and healthcare organizations have significant purchasing power, which can put pressure on distributors' margins.

Valuation

After reaching nearly $1,000 earlier in 2026, MCK is still trading at a premium compared with its historical levels. (MarketWatch)

A strong company can still produce disappointing returns if investors pay too much for its future earnings.

Why MCK Could Rally

Several potential catalysts could push the stock higher:

• Continued double-digit EPS growth

• Strong oncology demand

• Expansion of biopharma services

• Higher-margin specialty healthcare growth

• Share repurchases

• Continued dividend increases

• Operating leverage

• Strong free cash flow

• Further upgrades to fiscal 2027 guidance

The company's long-term target of 13%–16% adjusted EPS growth is particularly noteworthy. (McKesson)

If McKesson can consistently achieve that growth while maintaining strong cash generation, the stock could justify a premium valuation.

What Could Hold the Stock Back?

The biggest concern is that expectations are already high.

MCK has already delivered significant earnings growth and enjoyed a major stock-price run. If future results merely meet expectations rather than exceed them, the valuation multiple could compress.

Healthcare-policy changes are another risk.

Drug pricing reforms, reimbursement pressure and changes in pharmaceutical distribution economics could affect profitability.

Investors should also watch whether McKesson's higher-growth segments actually deliver the targeted operating-profit expansion.

Final Verdict

McKesson looks like one of the stronger healthcare compounders for long-term investors, but the stock is no longer an obvious bargain.

The fundamental picture is impressive: fiscal 2026 revenue reached $403.4 billion, adjusted EPS increased 18%, free cash flow reached $5.4 billion, and management is targeting another 12%–14% adjusted EPS increase in fiscal 2027. (McKesson)

The company's transformation toward specialty pharmaceuticals, oncology, biopharma services and prescription technology provides additional growth beyond traditional pharmaceutical distribution.

Meanwhile, aggressive share repurchases and rising dividends could continue enhancing shareholder returns.

Bottom line: MCK appears to be a high-quality healthcare growth-and-cash-flow story, rather than merely a defensive pharmaceutical distributor. The recent pullback from its $999 52-week high makes the stock more interesting, but investors should still pay attention to valuation before buying aggressively. (MarketWatch)

For long-term investors, MCK is worth considering on pullbacks, particularly if earnings continue growing in the targeted double-digit range. A sustained break back above its previous highs, supported by further EPS upgrades, could strengthen the bullish case.

Verdict: BUY ON PULLBACKS / LONG-TERM BULLISH.

This article is for informational and educational purposes only and is not personalized financial advice.